ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation

Reuters

2025/06/24

ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation

ImmunoPrecise Antibodies Ltd. $(IPA)$, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared "Achilles' heel" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545676289"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545676289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545676289?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545676289","market":"nz","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. <a href=\"https://laohu8.com/S/IPA\">$(IPA)$</a>, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. <a href=\"https://laohu8.com/S/IPA\">$(IPA)$</a>, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL8tjm8z:1","article_id":"2545676289","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545676289","pubTimestamp":1750762941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation. ImmunoPrecise Antibodies Ltd. , a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.Disclaimer: This news brief was","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务"},"translate_title":"ImmunoPrecise Antibodies宣布通用登革热疫苗开发取得突破，人工智能驱动的安全性和有效性验证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"ImmunoPrecise Antibodies Announces Breakthrough in Universal Dengue Vaccine Development with AI-Driven Safety and Efficacy Validation\n    \n\n        ImmunoPrecise Antibodies Ltd. $(IPA)$, a leader in AI-driven biotherapeutics, has announced a significant advancement in the development of a universal dengue vaccine. Following a previous announcement on June 5, 2025, the company has now validated its computationally discovered vaccine target using its proprietary LENSai platform and patented HYFT technology. The target, identified as a shared \"Achilles' heel\" across all four dengue virus types, has been confirmed to be safe, immunologically active, and structurally stable. This validation strengthens the translational potential of the vaccine candidate, which is now being prepared for further preclinical evaluation. Results from this study have already been presented, and ImmunoPrecise is engaging with global stakeholders to explore future development and funding opportunities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624850812) on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}